CD274 and neoplasm: Currently, tumour PD‐L1 expression is used as a predictive biomarker for immunotherapy targeting on the PD1/PD‐L1 axis.6 PD‐L1 appears to be expressed in a substantial proportion of human MPM.12, 24 Our IHC staining results also showed that 22.9% of human MPM had strong expression of PD‐L1, which indicate that some patients with MPM might benefit from anti‐PD‐1/PD‐L1 immunotherapy.